<h1 style="font-family: 'Sommet Bold'; font-size: 18pt; color: #3f762b; font-weight: 900;">Key Findings</h1>
<ul>
    <li>27 cryptomarkets were monitored in the period from 4th October 2018 to 30th September 2021. Nine of these markets closed - Dream Market, Empire, Apollon, Tochka, DarkBay, Berlusconi, Wall Street, Cryptonia and CGMC - while the other 18 remained open as at the end of September 2021.</li>
    <li>There were 3,125,029 listings in total over the monitoring period, comprising 1,893,053 listings in the first period between 1st October 2018 and 13th Feb 2020 and 1,231,976 listings in the second period between 4th February 2021 and 30th September 2021. When deduplicated for week of scraping, we identified 454,940 unique listings.</li>
    <iframe frameborder="0" height="800" src="https://drugtrends.github.io/DNeT-2021-09/F1.html" width="100%"> </iframe><p><small>Note: See our <a href="https://drugtrends.shinyapps.io/cryptomarkets/?_inputs_&amp;date=%5B%222014-01-30%22%2C%222021-05-31%22%5D&amp;DDrug=%22All%22&amp;Detail=false&amp;Drop=%22Gant%22">interactive timeline</a> for a complete historical record of all cryptomarkets monitored since January 2014. Data between 14th February 2020 and 3rd February 2021 in the pink region were excluded. Breaks indicate period where market crawling was not achievable. The width of the bar is proportional to the log of the number of drug listings observed in each week for each market.</small></p>
    <li>Dream Market, Empire and White House were the biggest cryptomarkets in the period with a maximum of 44,681, 21,405 and 19,705 listings in a weekly scrape, respectively.</li>
    <iframe frameborder="0" height="980" src="https://drugtrends.github.io/DNeT-2021-09/F2-week.html" width="100%"> </iframe><p><small>Note: Data between 14th February 2020 and 3rd February 2021 in the pink region were excluded.</small></p>
    <li>There were 14,133 vendor entities identified with an average of 2,054 of them in a weekly scrape. About 30% of vendors listed across two or more markets. When ranked by number of listings in a weekly scrape, the average proportion of listings from the top 1% of vendors was 12.0%, which is similar to the proportion of 12.1% from the bottom 50% of vendors.</li>
    <li>The largest proportion of listings originated from Europe (57.6%), followed by North America (26.0%), Oceania (3.9%) and Asia (2.8%).</li>
    <li>About two-thirds of listings originated four countries: United States (23.4%), United Kingdom (22.2%), Germany (11.3%), Netherlands (10.7%). Australia had the fifth highest number of listings (3.9%) followed by Canada (2.5%), France (2.1%) and Spain (1.9%). There are differences in the top three drug types originating from each country.</li>
    <iframe frameborder="0" height="700" src="https://drugtrends.github.io/DNeT-2021-09/F5-market.html" width="100%"> </iframe><p><small>Note: Data between 14th February 2020 and 3rd February 2021 in the pink region were excluded.</small></p>
    <li>Cannabis comprised about one-third of total listings over the period (34.8%). In the period before 13th February 2020, MDMA had the second highest percentage of listings, followed by cocaine or opioids (excluding heroin). In the period after 4th February 2021, benzodiazepines, cocaine or MDMA had the second to fourth highest percentage of drug listings after cannabis.</li>
    <li>Comparing September 2021 with October 2018, methamphetamine had the biggest increase in market share (by 2.1% from 4.9% to 7.0%), followed by cocaine (1.8% from 6.9% to 8.7%), benzodiazepines (1.7% from 5.9% to 7.6%), hallucinogenic mushroom (1.7% from 1.1% to 2.8%), LSD (1.6% from 3.2% to 4.8%) and ketamine (1.6% from 2.5% to 4.1%). In the same period, cannabis listings had the biggest decrease from 37.0% to 32.1%, followed by MDMA from 11.1% to 8.3% and PIEDS/weight loss drugs from 6.6% to 4.5%.</li>
    <iframe frameborder="0" height="650" src="https://drugtrends.github.io/DNeT-2021-09/F6-month.html" width="100%"> </iframe><p><small>Note: Data between 14th February 2020 and 3rd February 2021 in the pink region were excluded. Drugs that were <0.5% of listings in the period were grouped into the “All others” category. These are GHB/GBL/1,4-BD, paraphernalia, tobacco, MDA, e-cigarette, PCP, inhalants, and alcohol.</small></p>
    <li>Is market composition of interest in key findings???</li>
    <iframe frameborder="0" height="700" src="https://drugtrends.github.io/DNeT-2021-09/F8-segment.html" width="100%"> </iframe><p><small>Note: Data between 14th February 2020 and 3rd February 2021 in the pink region were excluded. Drugs that were <0.5% of listings in the period were grouped into the “All others” category. These are GHB/GBL/1,4-BD, paraphernalia, tobacco, MDA, e-cigarette, PCP, inhalants, and alcohol.</small></p>
    <li>PIEDS/weight loss drug listings had the highest percentage and number of listings from vendors in Australia until March 2019 when it was overtaken by cannabis and then by other drugs from December 2020 onwards.</li>
    <li>Similar to the global market, LSD (3.9%), ketamine (3.7%), meth/amphetamine (illicit) (2.1%), hallucinogenic mushroom (1.7%) and cocaine (1.7%) from Australia also increased their market share by >1%, while PIEDS/weight loss drugs (-14.8%) and MDMA (-1.7%) decreased by >1%.</li>
    <li>In contrast to the global market where cannabis market share decreased, cannabis from Australia increased (11.0%) in its market share from October 2018 to September 2021. There was also a decrease of >1% in Australian market share for opioids (excluding heroin) (-2.9%), other medicines (-2.3%) and new psychoactive substances (-1.1%).</li>
    <iframe frameborder="0" height="650" src="https://drugtrends.github.io/DNeT-2021-09/F9-month.html" width="100%"> </iframe><p><small>Note: Data between 14th February 2020 and 3rd February 2021 in the pink region were excluded. Drugs that were <0.5% of listings in the period were grouped into the “All others” category. These are GHB/GBL/1,4-BD, paraphernalia, tobacco, MDA, e-cigarette, PCP, inhalants, and alcohol.</small></p>
    <li>The unit price of powder cocaine over the monitoring period was consistently higher in Oceania compared with North America and Europe. Weeks of limited market availability resulted price spikes in February and April 2019.</li>
</ul>